NS3 Resistance-Associated Variants (RAVs) in Patients Infected with HCV Genotype 1a in Spain.
BACKGROUND:Resistance-associated variants have been related to treatment failure of hepatitis C virus (HCV) therapy with direct-acting antiviral drugs. The aim of our study was to analyze the prevalence of clinically relevant resistance-associated variants within NS3 in patients infected with HCV ge...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2016-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC5042525?pdf=render |
id |
doaj-3ed6148074464af397be871979cac879 |
---|---|
record_format |
Article |
spelling |
doaj-3ed6148074464af397be871979cac8792020-11-25T01:38:00ZengPublic Library of Science (PLoS)PLoS ONE1932-62032016-01-01119e016319710.1371/journal.pone.0163197NS3 Resistance-Associated Variants (RAVs) in Patients Infected with HCV Genotype 1a in Spain.María Ángeles Jimenez-SousaMónica Gutiérrez-RivasAlejandro Álvaro-MecaMónica García-ÁlvarezP Richard HarriganCesare Giovanni FedeleVerónica BrizSonia Vázquez-MorónSalvador ResinoBACKGROUND:Resistance-associated variants have been related to treatment failure of hepatitis C virus (HCV) therapy with direct-acting antiviral drugs. The aim of our study was to analyze the prevalence of clinically relevant resistance-associated variants within NS3 in patients infected with HCV genotype 1a (GT1a) in Spain. METHODS:We performed a cross-sectional study on 2568 patients from 115 hospitals throughout Spain (2014-2015). The viral NS3 protease gene was amplified by nested polymerase chain reaction and sequenced by Sanger sequencing using an ABI PRISM 377 DNA sequencer. Additionally, clade information for genotype 1a was obtained by using the software geno2pheno (http://hcv.geno2pheno.org/). RESULTS:In total, 875 out of 2568 samples were from human immunodeficiency virus (HIV)/HCV-coinfected patients. Q80K was the main RAV found in our patients (11.1%) and the rest of the resistance-associated variants had a lower frequency, including S122G (6.23%), T54S (3.47%), V55A (2.61%), and V55I (2.15%), which were among the most frequent after Q80K. Overall, 286 samples had the Q80K polymorphism (11.1%) and 614 (23.9%) were GT1a clade I. HIV/HCV-coinfected patients had a higher frequency of Q80K and GT1a clade I than HCV-monoinfected patients (12.9% vs. 9.6% [p = 0.012] and 28.5% vs. 21.4% [p<0.001], respectively). Both the prevalence of Q80K and GT1a clade I were not uniform throughout the country (p<0.001), which ranged from 7.3%-22.2% and 15.7%-42.5%, respectively. The frequency of the Q80K polymorphism was far higher in patients infected with GT1a clade I than in patients infected with GT1a clade II (41.5% vs. 1.6%; p<0.001). CONCLUSIONS:The prevalence of most resistance-associated variants in NS3 was low in patients infected with HCV GT1a in Spain, except for Q80K (11.1%), which was also notably higher in HIV/HCV-coinfected patients. The vast majority of Q80K polymorphisms were detected in GT1a clade I.http://europepmc.org/articles/PMC5042525?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
María Ángeles Jimenez-Sousa Mónica Gutiérrez-Rivas Alejandro Álvaro-Meca Mónica García-Álvarez P Richard Harrigan Cesare Giovanni Fedele Verónica Briz Sonia Vázquez-Morón Salvador Resino |
spellingShingle |
María Ángeles Jimenez-Sousa Mónica Gutiérrez-Rivas Alejandro Álvaro-Meca Mónica García-Álvarez P Richard Harrigan Cesare Giovanni Fedele Verónica Briz Sonia Vázquez-Morón Salvador Resino NS3 Resistance-Associated Variants (RAVs) in Patients Infected with HCV Genotype 1a in Spain. PLoS ONE |
author_facet |
María Ángeles Jimenez-Sousa Mónica Gutiérrez-Rivas Alejandro Álvaro-Meca Mónica García-Álvarez P Richard Harrigan Cesare Giovanni Fedele Verónica Briz Sonia Vázquez-Morón Salvador Resino |
author_sort |
María Ángeles Jimenez-Sousa |
title |
NS3 Resistance-Associated Variants (RAVs) in Patients Infected with HCV Genotype 1a in Spain. |
title_short |
NS3 Resistance-Associated Variants (RAVs) in Patients Infected with HCV Genotype 1a in Spain. |
title_full |
NS3 Resistance-Associated Variants (RAVs) in Patients Infected with HCV Genotype 1a in Spain. |
title_fullStr |
NS3 Resistance-Associated Variants (RAVs) in Patients Infected with HCV Genotype 1a in Spain. |
title_full_unstemmed |
NS3 Resistance-Associated Variants (RAVs) in Patients Infected with HCV Genotype 1a in Spain. |
title_sort |
ns3 resistance-associated variants (ravs) in patients infected with hcv genotype 1a in spain. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2016-01-01 |
description |
BACKGROUND:Resistance-associated variants have been related to treatment failure of hepatitis C virus (HCV) therapy with direct-acting antiviral drugs. The aim of our study was to analyze the prevalence of clinically relevant resistance-associated variants within NS3 in patients infected with HCV genotype 1a (GT1a) in Spain. METHODS:We performed a cross-sectional study on 2568 patients from 115 hospitals throughout Spain (2014-2015). The viral NS3 protease gene was amplified by nested polymerase chain reaction and sequenced by Sanger sequencing using an ABI PRISM 377 DNA sequencer. Additionally, clade information for genotype 1a was obtained by using the software geno2pheno (http://hcv.geno2pheno.org/). RESULTS:In total, 875 out of 2568 samples were from human immunodeficiency virus (HIV)/HCV-coinfected patients. Q80K was the main RAV found in our patients (11.1%) and the rest of the resistance-associated variants had a lower frequency, including S122G (6.23%), T54S (3.47%), V55A (2.61%), and V55I (2.15%), which were among the most frequent after Q80K. Overall, 286 samples had the Q80K polymorphism (11.1%) and 614 (23.9%) were GT1a clade I. HIV/HCV-coinfected patients had a higher frequency of Q80K and GT1a clade I than HCV-monoinfected patients (12.9% vs. 9.6% [p = 0.012] and 28.5% vs. 21.4% [p<0.001], respectively). Both the prevalence of Q80K and GT1a clade I were not uniform throughout the country (p<0.001), which ranged from 7.3%-22.2% and 15.7%-42.5%, respectively. The frequency of the Q80K polymorphism was far higher in patients infected with GT1a clade I than in patients infected with GT1a clade II (41.5% vs. 1.6%; p<0.001). CONCLUSIONS:The prevalence of most resistance-associated variants in NS3 was low in patients infected with HCV GT1a in Spain, except for Q80K (11.1%), which was also notably higher in HIV/HCV-coinfected patients. The vast majority of Q80K polymorphisms were detected in GT1a clade I. |
url |
http://europepmc.org/articles/PMC5042525?pdf=render |
work_keys_str_mv |
AT mariaangelesjimenezsousa ns3resistanceassociatedvariantsravsinpatientsinfectedwithhcvgenotype1ainspain AT monicagutierrezrivas ns3resistanceassociatedvariantsravsinpatientsinfectedwithhcvgenotype1ainspain AT alejandroalvaromeca ns3resistanceassociatedvariantsravsinpatientsinfectedwithhcvgenotype1ainspain AT monicagarciaalvarez ns3resistanceassociatedvariantsravsinpatientsinfectedwithhcvgenotype1ainspain AT prichardharrigan ns3resistanceassociatedvariantsravsinpatientsinfectedwithhcvgenotype1ainspain AT cesaregiovannifedele ns3resistanceassociatedvariantsravsinpatientsinfectedwithhcvgenotype1ainspain AT veronicabriz ns3resistanceassociatedvariantsravsinpatientsinfectedwithhcvgenotype1ainspain AT soniavazquezmoron ns3resistanceassociatedvariantsravsinpatientsinfectedwithhcvgenotype1ainspain AT salvadorresino ns3resistanceassociatedvariantsravsinpatientsinfectedwithhcvgenotype1ainspain |
_version_ |
1725055789995917312 |